202 related articles for article (PubMed ID: 1727373)
1. Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
Chari RV; Martell BA; Gross JL; Cook SB; Shah SA; Blättler WA; McKenzie SJ; Goldmacher VS
Cancer Res; 1992 Jan; 52(1):127-31. PubMed ID: 1727373
[TBL] [Abstract][Full Text] [Related]
2. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
3. Semisynthetic maytansine analogues for the targeted treatment of cancer.
Widdison WC; Wilhelm SD; Cavanagh EE; Whiteman KR; Leece BA; Kovtun Y; Goldmacher VS; Xie H; Steeves RM; Lutz RJ; Zhao R; Wang L; Blättler WA; Chari RV
J Med Chem; 2006 Jul; 49(14):4392-408. PubMed ID: 16821799
[TBL] [Abstract][Full Text] [Related]
4. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
5. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
Ojima I
Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of 2'-deoxy-5-fluorouridine conjugates against a murine thymoma and colon carcinoma xenografts.
Krauer KG; McKenzie IF; Pietersz GA
Cancer Res; 1992 Jan; 52(1):132-7. PubMed ID: 1530766
[TBL] [Abstract][Full Text] [Related]
7. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism.
Sun X; Widdison W; Mayo M; Wilhelm S; Leece B; Chari R; Singh R; Erickson H
Bioconjug Chem; 2011 Apr; 22(4):728-35. PubMed ID: 21391620
[TBL] [Abstract][Full Text] [Related]
8. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
[TBL] [Abstract][Full Text] [Related]
9. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins.
Dosio F; Arpicco S; Adobati E; Canevari S; Brusa P; De Santis R; Parente D; Pignanelli P; Negri DR; Colnaghi MI; Cattel L
Bioconjug Chem; 1998; 9(3):372-81. PubMed ID: 9576812
[TBL] [Abstract][Full Text] [Related]
10. Technology evaluation: C242-DM1, ImmunoGen Inc.
Smith S
Curr Opin Mol Ther; 2001 Apr; 3(2):198-203. PubMed ID: 11338934
[TBL] [Abstract][Full Text] [Related]
11. In vivo antitumor activity of a monoclonal antibody-Vinca alkaloid immunoconjugate directed against a solid tumor membrane antigen characterized by heterogeneous expression and noninternalization of antibody-antigen complexes.
Starling JJ; Maciak RS; Law KL; Hinson NA; Briggs SL; Laguzza BC; Johnson DA
Cancer Res; 1991 Jun; 51(11):2965-72. PubMed ID: 2032233
[TBL] [Abstract][Full Text] [Related]
12. Drug-conjugated monoclonal antibodies for the treatment of cancer.
Lambert JM
Curr Opin Pharmacol; 2005 Oct; 5(5):543-9. PubMed ID: 16087399
[TBL] [Abstract][Full Text] [Related]
13. Targeted anti-tumor agents and their cytotoxicity on gastric cancer cells in vitro.
Li S; Zhang XY; Chen XT; Fan DM; Tan LS; Pan HZ; Huang LQ
Chin Med J (Engl); 1990 May; 103(5):376-9. PubMed ID: 2118053
[TBL] [Abstract][Full Text] [Related]
14. [Targeting of antitumor drugs with monoclonal antibodies].
Monneret C; Florent JC
Bull Cancer; 2000 Nov; 87(11):829-38. PubMed ID: 11125291
[TBL] [Abstract][Full Text] [Related]
15. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
[TBL] [Abstract][Full Text] [Related]
16. [Immunoconjugates, drug-armed antibodies to fight against cancer].
Haeuw JF; Caussanel V; Beck A
Med Sci (Paris); 2009 Dec; 25(12):1046-52. PubMed ID: 20035677
[TBL] [Abstract][Full Text] [Related]
17. The use of daunomycin-antibody immunoconjugates in managing soft tissue sarcomas: nude mouse xenograft model.
Stastny JJ; Das Gupta TK
Cancer Res; 1993 Dec; 53(23):5740-4. PubMed ID: 8242630
[TBL] [Abstract][Full Text] [Related]
18. An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors.
Scott CF; Goldmacher VS; Lambert JM; Jackson JV; McIntyre GD
J Natl Cancer Inst; 1987 Nov; 79(5):1163-72. PubMed ID: 3500356
[TBL] [Abstract][Full Text] [Related]
19. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
20. Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity.
Guillemard V; Saragovi HU
Cancer Res; 2001 Jan; 61(2):694-9. PubMed ID: 11212270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
